[Effectiveness of antifungal agents for oral candidiasis in inpatients]

Mycotic stomatitis is one of the most frequent oral complications in cancer patients, but the effects of drug therapy for the disease are unknown. A prospective study was conducted to determine the effects of drug therapy for mycotic stomatitis in hospitalized patients, including cancer patients. ITCZ-OS and MCZ-GEL were used as antifungal agents. Atotal of 104 hospitalized patients were the study subjects for whom the Department of Dentistry was requested to provide dental treatment or oral care by other departments between March and May 20XX. Mycotic stomatitis was seen in 29%(n=30)of the subjects. Among subjects with mycotic stomatitis, 60%(n=18)had cancer, 57%(n=17)received steroids for two weeks or less, 57%(n=17)showed a performance status of 3 or 4, 70%(n=21)had mild to more severe xerostomia, and 53%(n=16)had an unclean oral cavity. As a result of drug therapy, the clinical symptom scores for white coat and flare and the total score were significantly improved on days 3 and 7 compared with before treatment, and the overall improvement rate was 83% on day 3 and 88% on day 7. Many patients hospitalized with mycotic stomatitis have cancer, and it was suggested that drug therapy is effective for them.